[go: up one dir, main page]

CL2013002033A1 - Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. - Google Patents

Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.

Info

Publication number
CL2013002033A1
CL2013002033A1 CL2013002033A CL2013002033A CL2013002033A1 CL 2013002033 A1 CL2013002033 A1 CL 2013002033A1 CL 2013002033 A CL2013002033 A CL 2013002033A CL 2013002033 A CL2013002033 A CL 2013002033A CL 2013002033 A1 CL2013002033 A1 CL 2013002033A1
Authority
CL
Chile
Prior art keywords
agent
preparation
prophylaxis
medicament
granules
Prior art date
Application number
CL2013002033A
Other languages
English (en)
Inventor
Yutaka Tanque
Tetsuya Matsuura
Naoki Nagahara
Yutaka Yamagata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567081&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002033(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CL2013002033A1 publication Critical patent/CL2013002033A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CL2013002033A 2011-01-17 2013-07-12 Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar. CL2013002033A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011007371 2011-01-17
JP2011227333 2011-10-14

Publications (1)

Publication Number Publication Date
CL2013002033A1 true CL2013002033A1 (es) 2014-01-03

Family

ID=45567081

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002033A CL2013002033A1 (es) 2011-01-17 2013-07-12 Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.

Country Status (24)

Country Link
US (6) US20120282191A1 (es)
EP (1) EP2665465A1 (es)
JP (3) JP5600747B2 (es)
KR (1) KR20140014134A (es)
CN (1) CN103429223A (es)
AR (1) AR084865A1 (es)
AU (1) AU2012207818B2 (es)
BR (1) BR112013017600A2 (es)
CA (1) CA2824430A1 (es)
CL (1) CL2013002033A1 (es)
CO (1) CO6791611A2 (es)
CR (1) CR20130380A (es)
EA (1) EA201391053A1 (es)
EC (1) ECSP13012825A (es)
IL (1) IL227357A0 (es)
MA (1) MA34908B1 (es)
MX (1) MX2013008314A (es)
PE (1) PE20140255A1 (es)
PH (1) PH12013501512A1 (es)
SG (1) SG191964A1 (es)
TW (1) TW201309347A (es)
UY (1) UY33869A (es)
WO (1) WO2012099260A1 (es)
ZA (1) ZA201305567B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
JP6245677B2 (ja) * 2012-01-20 2017-12-13 ニプロ株式会社 口腔内崩壊錠
CN103989643B (zh) * 2013-07-26 2018-10-30 武汉先路医药科技有限公司 含有雷美替胺和共聚维酮的片剂
HK1222796A1 (zh) * 2013-07-31 2017-07-14 因特根克斯公司 不含表面活性剂或多元醇的即时可湿性口服薄膜剂型
CN105007904A (zh) * 2014-02-07 2015-10-28 科学实验室药物公司 全天然无毒舌下药物递送系统
CN106389361A (zh) * 2016-03-31 2017-02-15 北京万全德众医药生物技术有限公司 一种含有雷美替胺的口腔崩解片及其制备方法
CN105853379A (zh) * 2016-03-31 2016-08-17 北京万全德众医药生物技术有限公司 一种雷美替胺分散片及其制备工艺
CA3023305C (en) 2016-05-06 2024-07-02 Societe Des Produits Nestle S.A. COMPOSITION OF VALERIAN AND ASSOCIATED PROCESSES
CN106038502A (zh) * 2016-07-01 2016-10-26 北京万全德众医药生物技术有限公司 一种雷美替胺口崩片及其制备方法
US20210113456A1 (en) * 2017-07-13 2021-04-22 Maxinase Life Sciences Limited Pharmaceutical compositions of ramelteon and methods of use thereof
US11648201B2 (en) 2018-05-02 2023-05-16 Ferring B.V. Pharmaceutical formulations
JP7552146B2 (ja) * 2019-08-28 2024-09-18 小野薬品工業株式会社 イバブラジンを含有する錠剤
CN113243444A (zh) * 2020-02-13 2021-08-13 罗盖特公司 作为口香糖中的填充剂的多孔淀粉
JP7611556B2 (ja) * 2020-05-28 2025-01-10 日医工株式会社 服用性、安定性等に優れた医薬組成物
CN115778925A (zh) * 2022-12-26 2023-03-14 湖北广济医药科技有限公司 一种雷美替胺口溶膜剂及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
CA2258159C (en) 1996-06-14 2006-03-21 Kyowa Hakko Kogyo Co., Ltd. Intraorally rapidly disintegrable tablet
JP3460538B2 (ja) 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
ES2559766T3 (es) * 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
EP1153616B1 (en) 1999-02-15 2004-12-01 Sumitomo Pharmaceuticals Company, Limited Tablets quickly disintegrated in the oral cavity
CA2381860C (en) * 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
JP4802436B2 (ja) 2000-04-12 2011-10-26 Ｍｓｄ株式会社 口腔内崩壊型組成物及び口腔内崩壊型製剤
US7008642B1 (en) * 2001-02-12 2006-03-07 Advanced Cardiovascular Systems, Inc. Compositions for achieving a therapeutic effect in an anatomical structure and methods of using the same
WO2003028706A1 (fr) * 2001-09-28 2003-04-10 Sanwa Kagaku Kenkyusho Co.,Ltd Double comprime a desintegration rapide
FR2834890B1 (fr) 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
US20040161459A1 (en) * 2002-12-31 2004-08-19 Ngoc Do Fast-dissolve tablet technology
WO2005063240A1 (en) * 2003-12-22 2005-07-14 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
GEP20105001B (en) 2005-04-04 2010-06-10 Takeda Pharmaceuticals Co Preventive or remedy for depression or anxiety neurosis
WO2007010173A1 (en) * 2005-07-18 2007-01-25 Colin Lawrence Amess Electrostatic air filter
PE20070698A1 (es) * 2005-11-14 2007-08-17 Teijin Pharma Ltd Comprimido de disgregacion rapida intraoral que contiene hidrocloruro de ambroxol
FR2894475B1 (fr) 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
EP1967211A4 (en) * 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
AU2007253684A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
US7797869B2 (en) * 2006-07-10 2010-09-21 Tollis David R Multi-section display and utility stanchion
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
EP2133096A4 (en) 2007-03-13 2011-11-16 Dainippon Sumitomo Pharma Co IN THE MOUTHING TABLET
RU2485949C2 (ru) * 2007-04-11 2013-06-27 Фармасьютикал Продакшнс Инк Таблетка мелатонина и способы изготовления и применения
WO2009060318A2 (en) * 2007-07-12 2009-05-14 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ramelteon and processes for preparation thereof
JP2009114113A (ja) * 2007-11-06 2009-05-28 Nipro Corp 口腔内崩壊錠及びその製造方法
JP2009136240A (ja) 2007-12-10 2009-06-25 Lion Corp チューインガム組成物
US20110130428A1 (en) 2008-06-11 2011-06-02 Astrazeneca Ab Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine
US7833819B2 (en) * 2008-07-23 2010-11-16 Aptina Imaging Corporation Method and apparatus for decreasing storage node parasitic charge in active pixel image sensors
WO2010074753A1 (en) * 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
JP2011007371A (ja) 2009-06-23 2011-01-13 Sanyo Electric Co Ltd 空気調和機
JP5513936B2 (ja) * 2010-03-10 2014-06-04 全星薬品工業株式会社 口腔内崩壊製剤
JP5523913B2 (ja) 2010-04-21 2014-06-18 スタンレー電気株式会社 光源装置および照明装置

Also Published As

Publication number Publication date
CR20130380A (es) 2013-10-09
US20130035384A1 (en) 2013-02-07
CA2824430A1 (en) 2012-07-26
US20170065553A1 (en) 2017-03-09
JP5600747B2 (ja) 2014-10-01
MA34908B1 (fr) 2014-02-01
PE20140255A1 (es) 2014-03-11
KR20140014134A (ko) 2014-02-05
AU2012207818B2 (en) 2015-05-14
PH12013501512A1 (en) 2013-09-16
US8642649B2 (en) 2014-02-04
US8642648B2 (en) 2014-02-04
BR112013017600A2 (pt) 2016-10-18
US20120282191A1 (en) 2012-11-08
SG191964A1 (en) 2013-08-30
CN103429223A (zh) 2013-12-04
JP2013544230A (ja) 2013-12-12
MX2013008314A (es) 2013-09-26
WO2012099260A1 (en) 2012-07-26
US20130035385A1 (en) 2013-02-07
EA201391053A1 (ru) 2013-12-30
IL227357A0 (en) 2013-09-30
ZA201305567B (en) 2014-10-29
US20140235709A1 (en) 2014-08-21
JP2016053094A (ja) 2016-04-14
CO6791611A2 (es) 2013-11-14
AR084865A1 (es) 2013-07-10
TW201309347A (zh) 2013-03-01
US20140235879A1 (en) 2014-08-21
ECSP13012825A (es) 2013-10-31
AU2012207818A1 (en) 2013-05-02
EP2665465A1 (en) 2013-11-27
JP2014198723A (ja) 2014-10-23
UY33869A (es) 2012-08-31
NZ613265A (en) 2015-08-28

Similar Documents

Publication Publication Date Title
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CR11731A (es) Composiciones y procedimientos para su preparación y uso
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015002541A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
NI201600071A (es) Compuestos de inhibidor de autotaxina
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CL2014000732A1 (es) Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BR112012003280A2 (pt) composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto.
MX2016013236A (es) Formulacion inmunosupresora.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112012004851A2 (pt) agente para o tratamento e/ou profilaxia de um distúrbio de humor, derivado de tiazol, e, uso do derivado de tiazol
BR112012029606A2 (pt) formulação, método para a fabricação de uma fomulação, método de tratamento de uma planta e uso de uma formulação